This study investigated the enrichment of cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) by chemotherapy. SMMC-7721 cells were inoculated into mice treated with 0, 2, 5 or 10 mg/kg cyclophosphamide (CTX). Tissue from the resulting tumours was re-inoculated into CTX-treated mice two more times, thus producing three generations of tumour cells for each dose of CTX. Chromosome and fluorescence-activated cell sorting analyses were performed to determine the purity of the enriched cells. Sphere culture, colony formation and proliferation assays demonstrated that the self-renewal potential, proliferative activity and clonogenicity of the enriched cells in vitro increased with increasing chemotherapy dose and generation. The ability of the enriched cells to produce xenograft tumours in mice was also dependent on chemotherapy dose and generation. In conclusion, subjecting HCC cells to chemotherapy in vivo enriched the samples for HCC CSCs in a dose-and generation-dependent manner.
Introduction
Hepatocellular carcinoma (HCC) is the third most common cause of cancer mortality in China, and its incidence is rising in the western world due to an increased incidence of hepatitis C virus infection. 1 Although treatment with liver resection or transplantation is available for early-stage HCC, most patients are diagnosed at an advanced stage; for this reason, the mortality rate has not improved significantly for several decades. Furthermore, HCC is resistant to conventional chemotherapy and radiotherapy. As a consequence, these therapies are not effective and the prognosis for this disease is often poor.
It has been shown in malignancy that, while most cancer cells have relatively weak tumorigenicity, a small population of undifferentiated cells known as cancer stem cells (CSCs) drive cancer development and metastasis. 2, 3 These cells possess distinctive characteristics, including the ability to selfrenew, differentiate and proliferate following a prolonged period of quiescence. In addition, CSCs have unique survival mechanisms and are resistant to chemotherapy. The CSC hypothesis may explain why current chemotherapies are able to shrink primary tumours transiently, but are not able to eliminate them completely. It is probable that residual CSCs, which possess the ability to resist treatment, are able to survive in a dormant state for S Tan, JS Chen, LJ Sun et al. Selective enrichment of hepatocellular cancer stem cells many years after remission and then cause tumour relapse with renewed resilience and aggression. Thus the isolation and identification of CSCs is important for the development of new diagnostic and therapeutic strategies.
The existence of CSCs has been demonstrated in leukaemia and several solid tumours; CSCs have been successfully isolated and confirmed to possess tumorigenic capacity using non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice xenograft assays. 4 -7 Magnetic sorting and flow cytometry have been used to isolate CD133 + HCC cells, and these have been shown to display stem celllike characteristics; 8, 9 however, not all CSCs are CD133 + . Some studies have demonstrated that both CD133 + and CD133tumour cells possess stem cell-like properties, exhibiting distinct molecular profiles and growth characteristics in vitro and in vivo. 10 It is, therefore, essential to develop new methods to isolate HCC CSCs.
In this study, HCC CSCs were enriched by injecting the human HCC cell line SMMC-7721 into BALB/c-nu/nu mice treated with chemotherapy; cells from the tumours produced were isolated and injected into further mice to produce successive generations of tumour cells. The presence of distinctive stem cell-like characteristics was then investigated in vitro and in vivo in each generation of cells. Our findings may provide a platform for further investigation of the enrichment, isolation and characterization of CSCs in HCC development.
Materials and methods

HCC CELL LINES AND CULTURE
The HCC cell line SMMC-7721, which was established from a male HCC patient in 1977, 11 was obtained from the cell bank of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All adhered cells were cultured in RPMI 1640 medium (Invitrogen™, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) (HyClone, South Logan, UT, USA), supplemented with 100 IU/ml penicillin G and 100 µg/ml streptomycin (Sigma, St Louis, MO, USA). The cells were maintained at 37°C in a humidified incubator in the presence of 5% CO 2 .
GENERATION OF ENRICHED HCC CSCS
Male BALB/c-nu/nu mice 4 -5 weeks old were randomly divided into groups and bred under controlled conditions at the Animal Experiment Centre of Sun Yat-Sen University.
All animal experiments were approved by the Animal Care and Use Committee of Sun Yat-Sen University.
Each mouse was injected subcutaneously with 2 × 10 6 SMMC-7721 cells. When the xenograft tumours could be felt, cyclophosphamide (CTX) at a dose of 0, 2, 5 or 10 mg/kg was injected abdominally once a week. When the tumour size reached 1.5 cm, the mice were killed by cervical vertebra dislocation.
The tumour masses were excised and dissected. Some of the tumour tissue was digested by 1 mg/ml collagenase II (Sigma) for 1 h at 37°C with intermittent pipetting to disperse the cells prior to assay and analysis. The remaining tumour tissue was minced into tiny fragments (approximately 1 mm 3 ) and inoculated into CTX-treated BALB/cnu/nu mice as before. The resulting tumours were subsequently excised, the cells extracted and inoculated once more. In this way, three generations of tumour cells for each dose of CTX were produced for analysis.
CHROMOSOME ANALYSIS
Enriched cells at about 80% confluence were arrested by treatment with 0.05 mg/ml S Tan, JS Chen, LJ Sun et al. Selective enrichment of hepatocellular cancer stem cells vinblastine for 3 h at 37°C in a humidified incubator in the presence of 5% CO 2 . Mitotic cells were collected and incubated with 0.075 mol/l KCl at 37°C for 30 min, and then fixed with formalin and dyed with Giemsa dye.
FLOW CYTOMETRY
Cells were incubated with fluorescein isothiocyanate (FITC)-conjugated major histocompatibility complex (MHC) class I H-2Kd antibody (Abcam, Cambridge, MA, USA) at 4°C for 30 min, and were then analysed using fluorescence-activated cell sorting (FACS) with a FACS-Vantage Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and CellQuest software (BD Biosciences). Gating was implemented based on negative-control staining profiles.
SPHERE CULTURE
The self-renewal potential of enriched cells in vitro was assessed by investigating their ability to form spheres when cultured in suspension medium. Sphere culture was conducted as described elsewhere. 12 Briefly, cells (1 × 10 3 cells/ml) were cultured in suspension medium composed of serum-free Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (Invitrogen™) supplemented with 2% v/v of B27 (Invitrogen™), 20 ng/ml epidermal growth factor (BD Biosciences), 0.4% bovine serum albumin (Sigma) and 4 µg/ml insulin (Sigma). Cells were maintained at 37°C in a humidified incubator. After 7 days, the number of spheres was counted using a microscope.
COLONY FORMATION ASSAYS
The colony formation capacity of the enriched cells was investigated using soft agar colony formation and flat colony formation assays.
The soft agar colony formation assay was performed as previously published. 13 Briefly, cells were harvested and suspended in the suspension medium described above supplemented with agar at a final concentration of 0.33%. The resulting cell suspensions were plated in six-well plates covered with suspension medium supplemented with 0.66% agar, at a density of 2 × 10 4 cells/well, then cultured at 37°C in the presence of 5% CO 2 . After 10 days, the number of colony formations was counted using a microscope and calculated as a percentage of the total number of cells.
For the flat colony formation assay, cells (200 cells/well) were cultured in RPMI 1640 medium/10% FBS in six-well plates at 37°C. After 10 days, colonies were fixed with 4% paraformaldehyde and dyed with 0.05% crystal violet. The number of colony formations was counted using a microscope and calculated as a percentage of the total number of cells.
CELL PROLIFERATION ASSAY
Cell proliferation was evaluated by the methyltetrazolium (MTT) assay (Sigma), according to the manufacturer's instructions. A concentration of 2 × 10 3 cells/well was seeded in a 96-well plate. On days 1, 3, 5 and 7, the cells were incubated with 0.5 mg/ml MTT; 4 h later the medium was replaced with 100 µl dimethylsulphoxide and vortexed for 10 min. Absorbance was measured with a spectrophotometer (Labsystems Dragon, Helsinki, Finland) at a wavelength of 490 nm.
SIDE POPULATION ANALYSIS
It has been shown that CSCs over-express the ATP-binding cassette half transporter, ABCG2. 14 This property is correlated with the ability to expel dyes and was, therefore, used to quantify the side population by flow cytometry. The enriched cells were suspended in 10 mmol/l phosphate-buffered saline S Tan, JS Chen, LJ Sun et al. Selective enrichment of hepatocellular cancer stem cells (PBS), pH 7.4, supplemented with 2% FBS at a concentration of 1 × 10 6 cells/ml and incubated with 5 µg/ml Hoechst 33342 stain (Sigma) for 90 min at 37°C with intermittent mixing, either alone or in the presence of 50 µmol/l verapamil (Sigma). The cells were then spun down and resuspended in 4°C PBS. Samples were analysed on an Epics ® flow cytometer (Beckman Coulter, Fullerton, CA, USA). Excitation of Hoechst dye was performed using an ultraviolet laser at 350 nm, and the fluorescence was measured with a 450 nm/20-band pass filter (Hoechst Blue) and a 675 nm long pass edge optical filter (Hoechst Red) (Omega Optical, Brattleboro, VT, USA). A 610 nm dichroic mirror shortpass was used to separate the emission wavelengths.
XENOGRAFT TUMORIGENICITY ASSAY
An important feature of CSCs is efficient xenograft formation. 15 To validate and compare the tumorigenicity of the three generations, enriched cells in 200 µl PBS/Matrigel (BD Biosciences) (1:1) were injected subcutaneously into BALB/c-nu/nu mice (1 × 10 4 or 1 × 10 5 cells/mouse). Health was monitored daily and tumour size was measured weekly using calipers. When the size of the tumours reached 1.5 cm, or no more than 60 days after first being injected, the tumour-bearing mice were killed by cervical vertebra dislocation. Tumour masses were fixed in 10% neutral buffered formalin solution and then paraffin-embedded.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSIS
Formalin-fixed, paraffin-embedded tumour tissue sections were stained using haematoxylin and eosin. Immunohistochemistry was performed on sections that were dewaxed in xylene and rehydrated with distilled water. The slides were subsequently incubated with α-fetoprotein (AFP) antibody (Lab Vision-Neomarkers, Fremont, CA, USA) and hepatocyte antibody (Lab Vision-Neomarkers). The reactions were assessed using the Vectastain ® Elite ABC system (Vector Laboratories) and diaminobenzidine substrate chromogen (Dako, Glostrup, Denmark) followed by haematoxylin counterstaining.
STATISTICAL ANALYSIS
All in vitro experiments were conducted three or more times. Results were expressed as the mean ± SD. Differences between the mean values were evaluated using repeated measures analysis of variance. A P-value < 0.05 was considered to be statistically significant.
Results
PURITY OF ENRICHED HCC CELLS
Since the enriched cells were obtained from xenotransplanted tumours, it is possible that they might be interfused by mouse cells. Chromosome and FACS analyses were, therefore, performed to determine the purity of the enriched cells. The chromosomes of the enriched cells were found to be almost the same as those of the SMMC-7721 HCC cell line (Fig. 1A, 1B) ; only 4.13 ± 1.30% of the enriched cells were mouse cells ( Fig. 1C;  4 .00% in sample illustrated). These results indicated that the enriched cells were nearly all human HCC cells.
CHARACTERIZATION OF ENRICHED HCC CELLS IN VITRO
The number of spheres formed by enriched HCC cells increased with increasing CTX dose within each generation and with successive generations (Fig. 2) ; however, sphere formation in untreated cells decreased with successive generations. The S Tan, JS Chen, LJ Sun et al.
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sphere-formation capability of thirdgeneration cells treated with 10 mg/kg CTX was about three-fold higher than that of third-generation untreated cells. Spheres produced by third-generation cells treated with 10 mg/kg CTX could be seen after only 3 days' culture (data not shown). These results showed that the self-renewal potential of the enriched cells increased with chemotherapy in a dose-and generationdependent manner (P < 0.05 for generation; P < 0.01 for dose [repeated measures analysis of variance]).
Colony formation assays showed that the enriched cells efficiently formed colonies by day 10 in both soft agar (Fig. 3A, 3B ) and flat cultures (Fig. 3C, 3D ). In both types of culture, the capability for colony formation increased in dose-and generation-dependent manners (P < 0.01 for generation; P < 0.01 for dose [repeated measures analysis of variance]). Third-generation cells treated with 10 mg/kg CTX formed the most colonies in both soft agar (51.33 ± 2.08%) and flat cultures (37.33 ± 2.51%) whereas, in contrast, third-generation untreated cells formed the fewest colonies in both soft agar (3.67 ± 1.15%) and flat cultures (4.33 ± 1.15%).
On MTT assay, the growth curve ( Fig. 4 ) revealed that third-generation cells treated with 10 mg/kg CTX possessed the highest proliferative activity, while third-generation untreated cells had the lowest proliferative activity. As chemotherapy dose and generation increased, the proliferative activity of the enriched HCC cells was enhanced (P < 0.05 for generation; P < 0.05 for dose [repeated measures analysis of variance]).
On side population analysis, thirdgeneration cells treated with 10 mg/kg CTX contained the most side population cells, while third-generation untreated cells 
TUMORIGENICITY OF ENRICHED HCC CELLS
Third-generation cells treated with 10 mg/kg CTX showed the greatest tumorigenicity. All mice injected with 1 × 10 4 or 1 × 10 5 thirdgeneration cells treated with 10 mg/kg CTX developed tumours; these could be felt at about day 15 and had increased to about 1.5 cm in size by about day 55 (for size: P < 0.05 for generation; P < 0.05 for dose [repeated measures analysis of variance]). However, third-generation untreated cells showed the lowest tumorigenicity; none of the mice inoculated with 1 × 10 4 or 1 × 10 5 thirdgeneration untreated cells developed tumours by day 60 (Table 1 and Fig. 7) . The tumorigenicity of the enriched HCC cells increased, therefore, in dose-and generation-dependent manners.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSIS
Haematoxylin and eosin staining showed extensive necrosis in the centre of the tumours and around the cancer nests ( Fig.  8A -C) . In addition, the tumours expressed AFP (Fig. 8D, 8E ) and hepatocytes (Fig. 8F,  8G ), which identified them as HCC.
Discussion
In 1977, Hamburger and Salmon 16 conducted bioassays of human tumour stem cells and found that most tumours were heterogeneous, comprising cells with different phenotypes and different proliferative and malignant potentials. Since then a number of reports have shown that only a small subset of tumour cells are clonogenic in culture and in vivo. 4 -7 With regard to HCC, some studies have suggested that CD133 + HCC cells are CSCs, 8, 9 whereas Beier et al. 10 found that both CD133 + and CD133glioblastoma cells exhibited stem cell-like properties in vitro and in vivo. The tumorigenicity in vivo. These results are consistent with our previous study of breast CSCs. 17 Moreover, the enriched cells developed more CSC characteristics as the chemotherapy dose and generation increased, indicating that treating primary tumours by increasing the dose and number of chemotherapy cycles might not be effective.
One contributing factor for chemotherapy resistance in HCC CSCs is the drug efflux transporter ABCG2. The expression of ABCG2 has been shown to increase in HCC CSCs and to provide a selective survival advantage. 18 This has been used in previous studies to enrich HCC CSCs by selecting for side population cells that efflux Hoechst dyes. 18 In the present study, the proportion of side population cells in HCC increased in dose-and generation-dependent manners when subjected to chemotherapy. Ma et al. 19 reported that chemotherapy resistance in HCC CSCs was mediated through
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S Tan, JS Chen, LJ Sun et al. Selective enrichment of hepatocellular cancer stem cells preferential activation of the Akt/PKB and Bcl-2 cell survival pathways. In addition, it has been shown that glioma CSCs activated DNA repair pathways for selective survival under chemotherapy. 20 It is probable that multiple mechanisms are involved in the chemotherapy resistance and selective survival of CSCs; further research is needed to elucidate these mechanisms.
In this study, chemotherapy was shown to be an effective way to enrich HCC CSCs in dose-and generation-dependent manners. These results provide a platform for further investigation of the enrichment, isolation and characterization of HCC CSCs, and may eventually lead to the development of novel therapeutic procedures aimed at chemotherapy-resistant cells. 
